The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shimizu, J.
Right arrow Articles by Sakaguchi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shimizu, J.
Right arrow Articles by Sakaguchi, S.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Autoimmune Diseases
The Journal of Immunology, 1999, 163: 5211-5218.
Copyright © 1999 by The American Association of Immunologists

Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity1

Jun Shimizu*, Sayuri Yamazaki{dagger} and Shimon Sakaguchi2,*,{dagger}

* Department of Immunopathology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; and {dagger} Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan

This study shows that removal of a T cell subpopulation can evoke effective tumor immunity in otherwise nonresponding animals. Elimination of CD25-expressing T cells, which constitute 5–10% of peripheral CD4+ T cells in normal naive mice, elicited potent immune responses to syngeneic tumors in vivo and eradicated them. The responses were mediated by tumor-specific CD8+ CTLs and tumor-nonspecific CD4-8- cytotoxic cells akin to NK cells. Furthermore, in vitro culture of CD25+4+ T cell-depleted splenic cell suspensions prepared from tumor-unsensitized normal mice led to spontaneous generation of similar CD4-8- cytotoxic cells capable of killing a broad spectrum of tumors; reconstitution of CD25+4+ T cells inhibited the generation. In this culture, self-reactive CD25-4+ T cells responding to self peptides/class II MHC complexes on APCs spontaneously proliferated upon removal of CD25+4+ T cells, secreting large amounts of IL-2. The IL-2 thus produced appeared to be responsible for the generation of CD4-8- NK cells as lymphokine-activated killer cells, because direct addition of an equivalent amount of IL-2 to the culture of CD4-8- cells generated similar lymphokine-activated killer/NK cells, whereas coculture of normal CD4-8- cells with CD25-4+ T cells from IL-2-deficient mice did not. Thus, removal of immunoregulatory CD25+4+ T cells can abrogate immunological unresponsiveness to syngeneic tumors in vivo and in vitro, leading to spontaneous development of tumor-specific effector cells as well as tumor-nonspecific ones. This novel way of evoking tumor immunity would help to devise effective immunotherapy for cancer in humans.




This article has been cited by other articles:


Home page
QJMHome page
J. King, J. Waxman, and H. Stauss
Advances in tumour immunotherapy
QJM, September 1, 2008; 101(9): 675 - 683.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Watanabe, K. Deguchi, R. Zheng, H. Tamai, L.-x. Wang, P. A. Cohen, and S. Shu
Tumor-Induced CD11b+Gr-1+ Myeloid Cells Suppress T Cell Sensitization in Tumor-Draining Lymph Nodes
J. Immunol., September 1, 2008; 181(5): 3291 - 3300.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Laronne-Bar-On, D. Zipori, and N. Haran-Ghera
Increased Regulatory versus Effector T Cell Development Is Associated with Thymus Atrophy in Mouse Models of Multiple Myeloma
J. Immunol., September 1, 2008; 181(5): 3714 - 3724.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Nishikawa, T. Kato, M. Hirayama, Y. Orito, E. Sato, N. Harada, S. Gnjatic, L. J. Old, and H. Shiku
Regulatory T Cell-Resistant CD8+ T Cells Induced by Glucocorticoid-Induced Tumor Necrosis Factor Receptor Signaling
Cancer Res., July 15, 2008; 68(14): 5948 - 5954.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. J. Gough, C. E. Ruby, W. L. Redmond, B. Dhungel, A. Brown, and A. D. Weinberg
OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor
Cancer Res., July 1, 2008; 68(13): 5206 - 5215.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. Gil-Guerrero, J. Dotor, I. L. Huibregtse, N. Casares, A. B. Lopez-Vazquez, F. Rudilla, J. I. Riezu-Boj, J. Lopez-Sagaseta, J. Hermida, S. Van Deventer, et al.
In Vitro and In Vivo Down-Regulation of Regulatory T Cell Activity with a Peptide Inhibitor of TGF-{beta}1
J. Immunol., July 1, 2008; 181(1): 126 - 135.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Kline, I. E. Brown, Y.-Y. Zha, C. Blank, J. Strickler, H. Wouters, L. Zhang, and T. F. Gajewski
Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma
Clin. Cancer Res., May 15, 2008; 14(10): 3156 - 3167.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. E. C. Lutsiak, Y. Tagaya, A. J. Adams, J. Schlom, and H. Sabzevari
Tumor-Induced Impairment of TCR Signaling Results in Compromised Functionality of Tumor-Infiltrating Regulatory T Cells
J. Immunol., May 1, 2008; 180(9): 5871 - 5881.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
S. Piconese, B. Valzasina, and M. P. Colombo
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
J. Exp. Med., April 14, 2008; 205(4): 825 - 839.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
N. Larmonier, J. Cantrell, C. LaCasse, G. Li, N. Janikashvili, E. Situ, M. Sepassi, S. Andreansky, and E. Katsanis
Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression
J. Leukoc. Biol., April 1, 2008; 83(4): 1049 - 1059.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
X. Feng, S. Kajigaya, E. E. Solomou, K. Keyvanfar, X. Xu, N. Raghavachari, P. J. Munson, T. M. Herndon, J. Chen, and N. S. Young
Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro
Blood, April 1, 2008; 111(7): 3675 - 3683.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
L. Mascitelli and F. Pezzetta
Regulatory T Cells, Allergic Diseases, and Cancer
Chest, March 1, 2008; 133(3): 832 - 832.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Yokokawa, V. Cereda, C. Remondo, J. L. Gulley, P. M. Arlen, J. Schlom, and K. Y. Tsang
Enhanced Functionality of CD4+CD25highFoxP3+ Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer
Clin. Cancer Res., February 15, 2008; 14(4): 1032 - 1040.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Nishikawa, T. Tsuji, E. Jager, G. Briones, G. Ritter, L. J. Old, J. E. Galan, H. Shiku, and S. Gnjatic
Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector
Blood, February 1, 2008; 111(3): 1404 - 1412.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. Hu, R. S. Arias, R. E. Sadun, Y.-C. Nien, N. Zhang, H. Sabzevari, M.E. C. Lutsiak, L. A. Khawli, and A. L. Epstein
Construction and Preclinical Characterization of Fc-mGITRL for the Immunotherapy of Cancer
Clin. Cancer Res., January 15, 2008; 14(2): 579 - 588.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Haas, L. Schopp, B. Storch-Hagenlocher, B. Fritzsching, C. Jacobi, L. Milkova, B. Fritz, A. Schwarz, E. Suri-Payer, M. Hensel, et al.
Specific recruitment of regulatory T cells into the CSF in lymphomatous and carcinomatous meningitis
Blood, January 15, 2008; 111(2): 761 - 766.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. Degl'Innocenti, M. Grioni, G. Capuano, E. Jachetti, M. Freschi, M. T.S. Bertilaccio, R. Hess-Michelini, C. Doglioni, and M. Bellone
Peripheral T-Cell Tolerance Associated with Prostate Cancer Is Independent from CD4+CD25+ Regulatory T Cells
Cancer Res., January 1, 2008; 68(1): 292 - 300.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Li and C. Yee
IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes
Blood, January 1, 2008; 111(1): 229 - 235.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. Vence, A. K. Palucka, J. W. Fay, T. Ito, Y.-J. Liu, J. Banchereau, and H. Ueno
Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma
PNAS, December 26, 2007; 104(52): 20884 - 20889.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. Zhou, L. L'italien, D. Hodges, and X. M. Schebye
Pivotal Roles of CD4+ Effector T cells in Mediating Agonistic Anti-GITR mAb-Induced-Immune Activation and Tumor Immunity in CT26 Tumors
J. Immunol., December 1, 2007; 179(11): 7365 - 7375.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
T. L. Guo, R. P. Chi, D. M. Hernandez, W. Auttachoat, and J. F. Zheng
Decreased 7,12-dimethylbenz[a]anthracene-induced carcinogenesis coincides with the induction of antitumor immunities in adult female B6C3F1 mice pretreated with genistein
Carcinogenesis, December 1, 2007; 28(12): 2560 - 2566.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Leon, K. Garcia, J. Carneiro, and A. Lage
How Regulatory CD25+CD4+ T Cells Impinge on Tumor Immunobiology: The Differential Response of Tumors to Therapies
J. Immunol., November 1, 2007; 179(9): 5659 - 5668.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. T. Litzinger, R. Fernando, T. J. Curiel, D. W. Grosenbach, J. Schlom, and C. Palena
IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity
Blood, November 1, 2007; 110(9): 3192 - 3201.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
R. Sutmuller, A. Garritsen, and G. J Adema
Regulatory T cells and toll-like receptors: regulating the regulators
Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii91 - iii95.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. Chaput, G. Darrasse-Jeze, A.-S. Bergot, C. Cordier, S. Ngo-Abdalla, D. Klatzmann, and O. Azogui
Regulatory T Cells Prevent CD8 T Cell Maturation by Inhibiting CD4 Th Cells at Tumor Sites
J. Immunol., October 15, 2007; 179(8): 4969 - 4978.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. Ambrosino, M. Terabe, R. C. Halder, J. Peng, S. Takaku, S. Miyake, T. Yamamura, V. Kumar, and J. A. Berzofsky
Cross-Regulation between Type I and Type II NKT Cells in Regulating Tumor Immunity: A New Immunoregulatory Axis
J. Immunol., October 15, 2007; 179(8): 5126 - 5136.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. E. Clark, S. R. Hingorani, R. Mick, C. Combs, D. A. Tuveson, and R. H. Vonderheide
Dynamics of the Immune Reaction to Pancreatic Cancer from Inception to Invasion
Cancer Res., October 1, 2007; 67(19): 9518 - 9527.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Brouard, E. Mansfield, C. Braud, L. Li, M. Giral, S.-c. Hsieh, D. Baeten, M. Zhang, J. Ashton-Chess, C. Braudeau, et al.
Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance
PNAS, September 25, 2007; 104(39): 15448 - 15453.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. Hyka-Nouspikel, L. Lucian, E. Murphy, T. McClanahan, and J. H. Phillips
DAP10 Deficiency Breaks the Immune Tolerance against Transplantable Syngeneic Melanoma
J. Immunol., September 15, 2007; 179(6): 3763 - 3771.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. M. Paulos, A. Kaiser, C. Wrzesinski, C. S. Hinrichs, L. Cassard, A. Boni, P. Muranski, L. Sanchez-Perez, D. C. Palmer, Z. Yu, et al.
Toll-like Receptors in Tumor Immunotherapy
Clin. Cancer Res., September 15, 2007; 13(18): 5280 - 5289.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
V. S. Zimmermann, A. Casati, C. Schiering, S. Caserta, R. Hess Michelini, V. Basso, and A. Mondino
Tumors Hamper the Immunogenic Competence of CD4+ T Cell-Directed Dendritic Cell Vaccination
J. Immunol., September 1, 2007; 179(5): 2899 - 2909.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Harrop, N. Drury, W. Shingler, P. Chikoti, I. Redchenko, M. W. Carroll, S. M. Kingsman, S. Naylor, A. Melcher, J. Nicholls, et al.
Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Chemotherapy Induces Potent Immune Responses
Clin. Cancer Res., August 1, 2007; 13(15): 4487 - 4494.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. Sabbatini and K. Odunsi
Immunologic Approaches to Ovarian Cancer Treatment
J. Clin. Oncol., July 10, 2007; 25(20): 2884 - 2893.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Zhang, A. L. Cote, V. C. de Vries, E. J. Usherwood, and M. J. Turk
Induction of Postsurgical Tumor Immunity and T-Cell Memory by a Poorly Immunogenic Tumor
Cancer Res., July 1, 2007; 67(13): 6468 - 6476.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Tuve, B.-M. Chen, Y. Liu, T.-L. Cheng, P. Toure, P. S. Sow, Q. Feng, N. Kiviat, R. Strauss, S. Ni, et al.
Combination of Tumor Site-Located CTL-Associated Antigen-4 Blockade and Systemic Regulatory T-Cell Depletion Induces Tumor-Destructive Immune Responses
Cancer Res., June 15, 2007; 67(12): 5929 - 5939.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. P. Singh, A. La Cava, M. Wong, F. Ebling, and B. H. Hahn
CD8+ T Cell-Mediated Suppression of Autoimmunity in a Murine Lupus Model of Peptide-Induced Immune Tolerance Depends on Foxp3 Expression
J. Immunol., June 15, 2007; 178(12): 7649 - 7657.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. G. Elpek, C. Lacelle, N. P. Singh, E. S. Yolcu, and H. Shirwan
CD4+CD25+ T Regulatory Cells Dominate Multiple Immune Evasion Mechanisms in Early but Not Late Phases of Tumor Development in a B Cell Lymphoma Model
J. Immunol., June 1, 2007; 178(11): 6840 - 6848.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. H. Kim, M. Duvic, E. Obitz, R. Gniadecki, L. Iversen, A. Osterborg, S. Whittaker, T. M. Illidge, T. Schwarz, R. Kaufmann, et al.
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma
Blood, June 1, 2007; 109(11): 4655 - 4662.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. Weng, J. Dyson, and F. Dazzi
Low-intensity transplant regimens facilitate recruitment of donor-specific regulatory T cells that promote hematopoietic engraftment
PNAS, May 15, 2007; 104(20): 8415 - 8420.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Sinha, V. K. Clements, A. M. Fulton, and S. Ostrand-Rosenberg
Prostaglandin E2 Promotes Tumor Progression by Inducing Myeloid-Derived Suppressor Cells
Cancer Res., May 1, 2007; 67(9): 4507 - 4513.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. Rudge, S. P. Barrett, B. Scott, and I. R. van Driel
Infiltration of a Mesothelioma by IFN-{gamma}-Producing Cells and Tumor Rejection after Depletion of Regulatory T Cells
J. Immunol., April 1, 2007; 178(7): 4089 - 4096.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. N. Couper, D. G. Blount, J. B. de Souza, I. Suffia, Y. Belkaid, and E. M. Riley
Incomplete Depletion and Rapid Regeneration of Foxp3+ Regulatory T Cells Following Anti-CD25 Treatment in Malaria-Infected Mice
J. Immunol., April 1, 2007; 178(7): 4136 - 4146.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
U. Galili, K. Wigglesworth, and U. M. Abdel-Motal
Intratumoral Injection of {alpha}-gal Glycolipids Induces Xenograft-Like Destruction and Conversion of Lesions into Endogenous Vaccines
J. Immunol., April 1, 2007; 178(7): 4676 - 4687.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Kudo-Saito, E. K. Wansley, M. E. Gruys, R. Wiltrout, J. Schlom, and J. W. Hodge
Combination Therapy of an Orthotopic Renal Cell Carcinoma Model Using Intratumoral Vector-Mediated Costimulation and Systemic Interleukin-2
Clin. Cancer Res., March 15, 2007; 13(6): 1936 - 1946.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. S. Turner, P. A. Cohen, and O. J. Finn
Lack of Effective MUC1 Tumor Antigen-Specific Immunity in MUC1-Transgenic Mice Results from a Th/T Regulatory Cell Imbalance That Can Be Corrected by Adoptive Transfer of Wild-Type Th Cells
J. Immunol., March 1, 2007; 178(5): 2787 - 2793.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
V. C. Liu, L. Y. Wong, T. Jang, A. H. Shah, I. Park, X. Yang, Q. Zhang, S. Lonning, B. A. Teicher, and C. Lee
Tumor Evasion of the Immune System by Converting CD4+CD25- T Cells into CD4+CD25+ T Regulatory Cells: Role of Tumor-Derived TGF-beta
J. Immunol., March 1, 2007; 178(5): 2883 - 2892.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Liu, D. R. Breiter, G. Zheng, and A. Chen
Enhanced Antitumor Responses Elicited by Combinatorial Protein Transfer of Chemotactic and Costimulatory Molecules
J. Immunol., March 1, 2007; 178(5): 3301 - 3306.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
G. Zhou and H. I. Levitsky
Natural Regulatory T Cells and De Novo-Induced Regulatory T Cells Contribute Independently to Tumor-Specific Tolerance
J. Immunol., February 15, 2007; 178(4): 2155 - 2162.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Chen, S. Liu, D. Park, Y. Kang, and G. Zheng
Depleting Intratumoral CD4+CD25+ Regulatory T Cells via FasL Protein Transfer Enhances the Therapeutic Efficacy of Adoptive T Cell Transfer
Cancer Res., February 1, 2007; 67(3): 1291 - 1298.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. Kobayashi, N. Hiraoka, W. Yamagami, H. Ojima, Y. Kanai, T. Kosuge, A. Nakajima, and S. Hirohashi
FOXP3+ Regulatory T Cells Affect the Development and Progression of Hepatocarcinogenesis
Clin. Cancer Res., February 1, 2007; 13(3): 902 - 911.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Nair, D. Boczkowski, M. Fassnacht, D. Pisetsky, and E. Gilboa
Vaccination against the Forkhead Family Transcription Factor Foxp3 Enhances Tumor Immunity
Cancer Res., January 1, 2007; 67(1): 371 - 380.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
N. Ralainirina, A. Poli, T. Michel, L. Poos, E. Andres, F. Hentges, and J. Zimmer
Control of NK cell functions by CD4+CD25+ regulatory T cells
J. Leukoc. Biol., January 1, 2007; 81(1): 144 - 153.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Charalambous, M. Oks, G. Nchinda, S. Yamazaki, and R. M. Steinman
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
J. Immunol., December 15, 2006; 177(12): 8410 - 8421.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. J. Dobrzanski, J. B. Reome, J. C. Hylind, and K. A. Rewers-Felkins
CD8-Mediated Type 1 Antitumor Responses Selectively Modulate Endogenous Differentiated and Nondifferentiated T Cell Localization, Activation, and Function in Progressive Breast Cancer
J. Immunol., December 1, 2006; 177(11): 8191 - 8201.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Z.-Z. Yang, A. J. Novak, S. C. Ziesmer, T. E. Witzig, and S. M. Ansell
Attenuation of CD8+ T-Cell Function by CD4+CD25+ Regulatory T Cells in B-Cell Non-Hodgkin's Lymphoma.
Cancer Res., October 15, 2006; 66(20): 10145 - 10152.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Read, R. Greenwald, A. Izcue, N. Robinson, D. Mandelbrot, L. Francisco, A. H. Sharpe, and F. Powrie
Blockade of CTLA-4 on CD4+CD25+ Regulatory T Cells Abrogates Their Function In Vivo
J. Immunol., October 1, 2006; 177(7): 4376 - 4383.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
L. Melencio, R. J. McKallip, H. Guan, R. Ramakrishnan, R. Jain, P. S. Nagarkatti, and M. Nagarkatti
Role of CD4+CD25+ T regulatory cells in IL-2-induced vascular leak
Int. Immunol., October 1, 2006; 18(10): 1461 - 1471.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. Hiraoka, K. Onozato, T. Kosuge, and S. Hirohashi
Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions.
Clin. Cancer Res., September 15, 2006; 12(18): 5423 - 5434.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
C. T. Viehl, T. T. Moore, U. K. Liyanage, D. M. Frey, J. P. Ehlers, T. J. Eberlein, P. S. Goedegebuure, and D. C. Linehan
Depletion of CD4+CD25+ Regulatory T Cells Promotes a Tumor-Specific Immune Response in Pancreas Cancer-Bearing Mice